Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | PPARD | Q03181 | 6/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MDH1 | P40925 | 1/20 | 0.41 |
| ▸ | MDH2 | P40926 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991862 | 0.96 | MAPK14 (0.44) | TRPV1ALDH1A1PPARAPPARDPPARG | |
| SCHEMBL21991835 | 0.89 | MAOB (0.59) | PPARAPPARDPPARGMAOB | |
| SCHEMBL21992549 | 0.85 | POLB (0.48) | TRPV1PPARAPPARDPPARGMAOB | |
| SCHEMBL21991498 | 0.84 | KMT2A (0.41) | ALDH1A1PPARALMNAHTT | |
| SCHEMBL21992551 | 0.84 | PPARA (0.47) | TRPV1ALDH1A1PPARAPPARDPPARG | |
| SCHEMBL21992547 | 0.84 | TRPV1 (0.43) | TRPV1ALDH1A1PPARAPPARDPPARG | |
| SCHEMBL21991504 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNAHTT | |
| SCHEMBL23605972 | 0.82 | MAPT (0.42) | ALDH1A1PPARAPPARDLMNAHTT | |
| SCHEMBL21906426 | 0.82 | KMT2A (0.46) | ALDH1A1PPARAPPARGLMNAHTT | |
| SCHEMBL21992629 | 0.81 | POLB (0.45) | PPARAPPARDPPARGMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TRPV1 1213/4885ALDH1A1 932/4885PPARA 806/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | TRPV1 1213/4885ALDH1A1 932/4885PPARA 806/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TRPV1 1213/4885ALDH1A1 932/4885PPARA 806/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TRPV1 1213/4885ALDH1A1 932/4885PPARA 806/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TRPV1 1213/4885ALDH1A1 932/4885PPARA 806/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TRPV1 1213/4885ALDH1A1 932/4885PPARA 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.